Pediatric nephrology (Berlin, Germany) · 2021
Fenoldopam and renal hemodynamics in shiga toxin-related hemolytic uremic syndrome.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ardissino Gianluigi, Giussani Antenore, Capone Valentina, Testa Sara, Gandini Cristiano, Montini Giovanni, ItalKid-HUS Network
Аннотация
BACKGROUND: Fenoldopam, a vasodilating agent, may represent a potential therapeutic opportunity to increase renal perfusion in those conditions where renal hemodynamics are severely impaired by vascular sub-occlusion, as, indeed, is the case in thrombotic microangiopathies.
METHODS: The renal resistance index (RRI) was measured, on and off fenoldopam, in 27 children with STEC-HUS.
RESULTS: A 12% decrease in RRI was observed on fenoldopam compared to off treatment without changes in the systemic hemodynamics and with no side effects.
CONCLUSIONS: If confirmed in larger series, fenoldopam may become an important addition to supportive care to reduce ischemic damage in STEC-HUS and improve long-term outcomes.
METHODS: The renal resistance index (RRI) was measured, on and off fenoldopam, in 27 children with STEC-HUS.
RESULTS: A 12% decrease in RRI was observed on fenoldopam compared to off treatment without changes in the systemic hemodynamics and with no side effects.
CONCLUSIONS: If confirmed in larger series, fenoldopam may become an important addition to supportive care to reduce ischemic damage in STEC-HUS and improve long-term outcomes.